Term ends Oct 6, 2031 · Low confidence
20-year base term ends Oct 6, 2031
Held by Mesoblast International Sàrl
Filed Dec 23, 2019 as application 16/725,677 · Granted Jul 25, 2023
Base term plus 816 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2011
2031
Clock starts
Oct 6, 2011
Oct 6, 2011
Term ends
Oct 6, 2031
Oct 6, 2031
Granted
Jul 25, 2023
Jul 25, 2023
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
816
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 9,963,678.
1 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 816 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 1 of 2 maintenance fees is paid so far. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 6, 2011, when application 13/267,363, the earliest non-provisional in its chain, was filed (this one was filed Dec 23, 2019); a parent in its chain could not be resolved (the next row) | Oct 6, 2031 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +816 days, USPTO patent term adjustment record | Dec 30, 2033 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,963,678) | capped to Oct 6, 2031 | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Oct 6, 2031 | Low confidence |
This family
| Application 13/267,363 | Abandoned not computed | not computed |
| US 9,828,586 | In force Oct 2031 | Oct 2031 |
| US 9,963,678 | In force no later than Oct 2031 | no later than Oct 2031 |
| US 10,550,369 | In force Jan 2032 | Jan 2032 |
| US 11,708,560 | this patent Oct 2031 | Oct 2031 |
| US 12,410,405 | In force Oct 2031 | Oct 2031 |
| Application 19/293,945 | Pending not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 15, 2020 Reel 51518, frame 476 | Osiris Therapeutics | Mesoblast International Sàrl | Assignment of Assignor's Interest |
| Jan 15, 2020 Reel 51518, frame 590 | Tom, Samson; Ton, Christopher; Danilkovitch, Alla | Osiris Therapeutics, Inc. | Assignment of Assignor's Interest |
| Dec 10, 2021 Reel 58957, frame 447 | Mesoblast Limited Acn 109 431 870; Mesoblast UK Limited; Mesoblast, Inc. (Formerly Known as Angioblast, Inc.); Mesoblast International Sàrl | Oaktree Fund Administration, LLC | Security Interest |
| Jan 2, 2026 Reel 74174, frame 183 | Oaktree Fund Administration, LLC, as Agent | Mesoblast Limited; Mesoblast UK Limited; Mesoblast, Inc. (Formerly Known as Angioblast, Inc.); Mesoblast International Sàrl | Release of Security Interest in Intellectual Property |
| Jan 2, 2026 reel/frame not recorded | Oaktree Fund Administration, LLC, as Agent | Mesoblast Limited | Release of Security Interest in Intellectual Property |
| Jan 2, 2026 reel/frame not recorded | Oaktree Fund Administration, LLC, as Agent | Mesoblast UK Limited | Release of Security Interest in Intellectual Property |
| Jan 2, 2026 reel/frame not recorded | Oaktree Fund Administration, LLC, as Agent | Mesoblast, Inc. (Formerly Known as Angioblast, Inc.) | Release of Security Interest in Intellectual Property |
| Jan 2, 2026 reel/frame not recorded | Oaktree Fund Administration, LLC, as Agent | Mesoblast International Sàrl | Release of Security Interest in Intellectual Property |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Oct 2031
Term ends Oct 6, 2031. Maintenance fees still fall due before then
Note
The 816 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 9,963,678.
Citations
5
later US patents cite this one
That is top 25% of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.